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AbstrAct
Among the various routes of drug delivery, oral route is the most preferred route. But conventional dosage form offers a few limitations which 
could be resolved by modifying the existing dosage form. Sustained and controlled drug delivery system helps in the maintenance of constant 
plasma drug concentration and retards the release rate of drug, thereby extending the duration of action. There are various formulation strategies 
for sustained-release tablets, among which matrix tablet serves as an important tool. Hence the problem like poor patient compliance, multiple 
dosing, see-saw fluctuations can be easily minimized. Matrix tablets can be formulated by either direct compression or wet granulation method 
by using a variety of hydrophilic or hydrophobic polymers. The rate of drug release from the matrix is primarily governed by rate and extent of 
water penetration, swelling of polymer, dissolution, and diffusion of the drug. Thus, a sustained release matrix tablet can offer better patient 
compliance and could be quite helpful in the treatment of chronic diseases. The present article concentrates on oral sustained-release tablets 
with a special emphasis on matrix tablets.
Keywords: Conventional tablet, Sustained-release, Controlled release, Polymer, Matrix tablet, Recent advancements.
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IntroductIon
The important role of a novel drug delivery system that improves 
the therapeutic effectiveness of incorporated drugs by providing 
sustained, controlled delivery and or targeting the drug to the 
desired site. Any drug delivery system aims to provide a therapeutic 
amount of drug to the specific site in the body to achieve promptly 
and then maintain the desired drug concentration.[1] The design 
of oral sustained release delivery systems is subjected to several 
interrelated variables of considerable importance, such as the 
type of delivery system, the disease being treated, the patient, 
the length of therapy, and the properties of the drug. Sustain 
release system includes any drug delivery systems that achieve 
slow release of a drug over a prolonged period.[2] Matrix tablets 
are considered to be the commercially feasible sustained action 
dosage forms that involve the least processing variables, utilize 
the conventional facilities and accommodate large doses of 
drug. There remains an interest in developing novel formulations 
that allow for sustained the drug release using readily available, 
inexpensive excipient by matrix-based formulation. During the last 
two decades, there has been a remarkable increase in interest in 
sustained release drug delivery system. This has been due to various 
factors like the prohibitive cost of developing new drug entities, 
expiration of existing international patients, the discovery of new 
polymeric materials suitable for prolonging the drug release, and 
the improvement in therapeutic efficiency and safety achieved by 
these delivery systems. Nowadays, the technology of sustained 
release is also being applied to veterinary products.[3] 
Gastrointestinal Tract (GIT)
The human gastrointestinal tract, or GI tract, or GIT is an organ 
system responsible for consuming and digesting foodstuffs, 
absorbing nutrients, and expelling waste. The tract consists of 
the stomach and intestines and is split into the upper and lower 
gastrointestinal tracts. The GI tract includes all structures across 
the mouth and the anus. On the other hand, the digestive system 
is a broader term that comprises other structures, including the 
digestive organs. The GI tract releases hormones to help regulate 
the digestive process. These hormones, including gastrin, secretin, 
cholecystokinin, and ghrelin. The track is divided into upper and 
lower tracts, and the intestines small and large parts:
Figure 1.1 (a): Digestive systems
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Upper Gastrointestinal Tract
The upper gastrointestinal tract composed of the esophagus, 
stomach, and duodenum. The exact demarcation across the upper 
and lower tracts is the suspensory ligament of the duodenum (also 
known as the Ligament of Treitz). This delineates the embryonic 
borders across the foregut and midgut and is also the division 
commonly used by clinicians to describe gastrointestinal bleeding 
as being of “upper” or “lower” origin.
Lower Gastrointestinal Tract
The lower gastrointestinal tract comprises most of the small intestine 
and all of the large intestine. In human anatomy, the intestine (or 
bowel, hose, or gut) is the segment of the gastrointestinal tract 
extending from the pyloric sphincter of the stomach to the anus 
and, in humans and other mammals, consists of two segments, 
the small intestine, and then large intestine. In humans, the small 
intestine is more likely subdivided into the duodenum, jejunum, 
and ileum while the large intestine is subdivided into the cecum, 
colon, rectum, and anal canal.
Principle of Sustained Release Drug Delivery
The conventional dosage forms release their active ingredients into 
an absorption pool immediately. This is illustrated in the following 
simple kinetic scheme in Figure 2.
The absorption pool represents a solution of the drug at the 
site of absorption, Kr, Ka, and Ke - first-order rate- constant for 
drug release, absorption, and overall elimination, respectively. 
Immediate drug release from a conventional dosage form 
implies that Kr >> Ka. For non-immediate release dosage forms, 
Kr << Ka, i.e., the release of drug from the dosage form is the 
rate-limiting step. The drug release from the dosage form 
should follow zero-order kinetics, as shown by the following 
equation:
Kr° = Rate In = Rate Out = Ke Cd Vd
Where, Kr°: Zero-order rate constant for drug release- Amount/
time, Ke: First-order rate constant for overall drug elimination-time, 
Cd: Desired drug level in the body – amount/volume, and Vd: volume 
space in which the drug is distributed in liter.[5]
The Following are the Rationale of Developing 
Sustained Release Matrix Drug Delivery System
• To extend the duration of action of the drug.
• To reduce the frequency of dosing.
• To minimize the fluctuations in the plasma level.
• Improved drug utilization.
• Less adverse effects.[6]
Advantages of Sustained Release Matrix Drug Delivery 
System
• The frequency of drug administration is reduced.
• Patient compliance can be improved.
• Drug administration can be made more convenient as well.
• The blood level oscillation characteristic of multiple dosing of 
conventional dosage forms is reduced.
• Better control of drug absorption can be attained since the high 
blood level peaks that may be observed after the administration 
of a dose of a high availability drug can be reduced.
• The characteristic blood level variations due to multiple dosing 
of conventional dosage forms can be reduced.
• The total amount of drug administered can be reduced, thus: 
Maximizing availability with a minimum dose. Minimize or 
eliminate local side effects. Minimize or eliminate systemic 
side effects. Minimize drug accumulation with chronic dosing.
• Safety margins of high potency drugs can be increased, and 
the incidence of both local and systemic adverse side effects 
can be reduced in sensitive patients.
• Economy.
Disadvantages of Sustained Release Matrix Drug 
Delivery System
• Probability of dose dumping.
• Reduced potential for dose adjustment.
• Cost of single unit higher than conventional dosage forms.
• Increase the potential for the first-pass metabolism.
• A requirement for additional patient education for proper 
medication.
Figure 1.1 (b): Upper gastrointestinal tract (stomach) Figure 1.1 (c): Lower gastrointestinal tract (Intestine)[4]
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Figure 2: Schematic representation of the kinetics of sustained-release DDS
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• Decreased systemic availability in comparison to immediate 
release conventional dosage forms.
• Poor in vitro and in vivo correlation.[7]
Criteria of Drug to be met to Formulate Sustained 
Release Dosage Forms
• Desirable half-life.
• High therapeutic index.
• Small dose.
• Desirable absorption and solubility characteristics.
• Desirable absorption window. 
• First past clearance.
Desirable Half-life
The half-life of a drug is an index of its residence time in the body. 
If the drug has a short half-life (less than 2 hours), the dosage form 
may contain a prohibitively large quantity of the drug. On the 
other hand, a drug with an elimination half-life of eight hours or 
more are sufficiently sustained in the body, when administered in 
conventional dosage form, and sustained release drug delivery 
system is generally not necessary in such cases. Ideally, the drug 
should have a half-life of 3-4 hours.
High Therapeutic Index
Drugs with low therapeutic index are unsuitable for incorporation 
in sustained-release formulations. If the system fails in the body, 
dose dumping may occur, leading to fatalities, eg. Digitoxin.
Small Dose
If the dose of a drug in the conventional dosage form is high, 
its suitability as a candidate for sustained release is seriously 
undermined. This is chiefly because the size of a unit dose sustained-
release formulation would become too big, to administer without 
difficulty.
Desirable Absorption and Solubility Characteristics
Absorption of poorly water-soluble drug is often dissolution rate 
limited. Incorporating such Compounds into sustained-release 
formulations is therefore unrealistic and may reduce overall 
absorption efficiency.
Desirable Absorption Window
Certain drugs, when administered orally, are absorbed only from a 
specific part of the gastrointestinal tract. This part is referred to as 
the ‘absorption window’. Drugs exhibiting an Absorption window 
like fluorouracil, thiazide diuretics, if formulated as sustained release 
dosage forms, are unsuitable.
First Pass Clearance
As discussed earlier in the disadvantages of a sustained delivery 
system, delivery of the drug to the body in desired concentrations 
is seriously hampered in case of drugs undergoing extensive 
hepatic first-pass metabolism when administered in sustained 
release forms.[9,10]
Classification of Matrix Tablets
Based on Retardant Material Used
Matrix tablets can be divided into 5 types.
• Hydrophobic Matrices (Plastic matrices)
In this method of obtaining sustained release from an oral dosage 
form, the drug is mixed with an inert or hydrophobic polymer and 
then compressed into a tablet. Sustained release is produced due 
to the fact that the dissolving drug has diffused through a network 
of channels that exist between compacted polymer particles. 
Examples of materials that have been used as inert or hydrophobic 
matrices include polyethylene, polyvinyl chloride, ethylcellulose, 
and acrylate polymers and their copolymers. The rate-controlling 
step in these formulations is liquid penetration into the matrix. The 
possible mechanism of release of drug in such type of tablets is 
diffusion. Such types of matrix tablets become inert in the presence 
of water and gastrointestinal fluid.[11]
• Lipid Matrices
These matrices prepared by the lipid waxes and related materials. 
Drug release from such matrices occurs through both pore diffusion 
and erosion. Release characteristics are, therefore, more sensitive to 
digestive fluid composition than to totally insoluble polymer matrix. 
Carnauba wax, in combination with stearyl alcohol or stearic acid, 
has been utilized for a retardant base for many sustained-release 
formulations.[12]
• Hydrophilic Matrices
Hydrophilic polymer matrix systems are widely used in oral 
controlled drug delivery because of their flexibility to obtain 
a desirable drug release profile, cost-effectiveness, and broad 
regulatory acceptance. A matrix is defined as a well-mixed 
composite of one or more drugs with a gelling agent (hydrophilic 
polymer). The polymers used in the preparation of hydrophilic 
matrices are divided into three broad groups.
Cellulose derivatives: Methylcellulose 400 and 4000 cps, 
hydroxyethylcellulose, hydroxypropylmethylcellulose (HPMC) 25, 
100, 4000, and 15000 cps; and Sodium carboxymethyl- cellulose.
Non-cellulose natural or semi-synthetic polymers: Agar-Agar; 
carob gum; alginates; molasses; polysaccharides of mannose and 
galactose, chitosan and modified starches. Polymers of acrylic acid: 
Carbopol-934, the most used variety.
• Biodegradable Matrices
These consist of the polymers which comprised of monomers 
linked to one another through functional groups and have unstable 
linkage in the backbone. They are biologically degraded or eroded 
by enzymes generated by surrounding living cells or by non-
Table 1: Characteristics of drug unsuitable for peroral sustained-release forms:
Characteristic Drugs
Not effectively absorbed in the lower intestine Riboflavin, Ferrous salts
Absorbed and excreted rapidly short biological half-life<1hr Penicillin G, Furosemide
Long biologic half-life (>12 hour.) Diazepam, Phenytoin
Large dose required > 1gm sulfonamide
Cumulative action and desirable side effect drug with low therapeutics indices Phenobarbital, Digitoxin
Precise dosage titrated to individual is required Anticoagulants, Cardiac glycosides[8]
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enzymatic processes into oligomers and monomers that can be 
metabolized or excreted. Examples are natural polymers such as 
proteins and polysaccharides, modified natural polymers, synthetic 
polymers such as aliphatic poly (esters), and poly anhydrides.
• Mineral Matrices
These consist of polymers which are obtained from various species 
of seaweeds. An example is Alginic acid, which is a hydrophilic 
carbohydrate obtained from species of brown seaweeds 
(Phaeophyceae) by the use of dilute alkali.[13]
On the Basis of Porosity of Matrix: Matrix tablets can be 
divided into 3 types
• Macroporous Systems
In such systems, the diffusion of the drug occurs through pores of 
a matrix, which are of size range 0.1 to 1 μm. This pore size is larger 
than the diffusion molecule size.
• Microporous System
Diffusion in this type of system occurs essentially through pores. For 
microporous systems, pore size ranges between 50–200 A°, which 
is slightly larger than diffusant molecules size.
• Non-porous System
Non-porous systems have no pores, and the molecules diffuse 
through the network meshes. In this case, only the polymeric phase 
exists, and no pore phase is present.[14,15]
Polymers used in the Matrix
The polymers most widely used in preparing matrix systems include 
both hydrophilic and hydrophobic polymers. 
Hydrophilic Polymers
Hydroxyl propyl methylcellulose (HPMC), hydroxyl propyl 
cellulose(HPC), hydroxyl ethyl cellulose (HEC), Xanthan gum, Sodium 
alginate, poly(ethylene oxide), and cross-linked homopolymers and 
copolymers of acrylic acid.
Hydrophobic Polymers
This usually includes waxes and water-insoluble polymers in their 
formulation.
Waxes
Carnauba wax, beeswax, candelilla wax, microcrystalline wax, 
ozokerite wax, paraff in waxes, and low molecular weight 
polyethylene.
Insoluble Polymers
Ammoniomethacrylate co-polymers (Eudragit RL100, PO, 
RS100, PO), ethylcellulose, cellulose acetate butyrate, cellulose 
acetate propionate and latex dispersion of methacrylic ester 
copolymers.[16] 
Characteristics of an Ideal Polymer
• It should be versatile and possess a wide rangeof mechanical, 
physical, chemical properties.
• It should be non-toxic and have good mechanical strength and 
should be easily administered
• It should be inexpensive and easy to fabricate.
• It should be inert to host tissue and compatible with the 
environment.
Criteria Followed in Polymer Selection
• The polymer should be soluble and easy to synthesis.
• It should have finite molecular weight.
• It should be compatible with the biological environment.
• It should be biodegradable.
• It should provide good drug-polymer linkage.
General Mechanism of Drug Release From Polymer
There are three primary mechanisms by which active agents can 
be released from a delivery system namely,
Diffusion
Diffusion occurs when a drug or other active agent passes through 
the polymer that forms the controlled-release device. Diffusion 
occurs when the drug passes from the polymer matrix into the 
external environment. As the release continues, its rate normally 
decreases with this type of system since the active agent has a 
progressively longer distance to travel and therefore requires a 
longer diffusion time to release. In these systems, the combinations 
of polymer matrices and bioactive agents have chosen must allow 
for the drug to diffuse through the pores or macromolecular 
structure of the polymer upon the introduction of the delivery 
Figure 3: Diagrammatic representation of Diffusion type drug release
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system into the biological environment without inducing any 
change in the polymer itself.[17]
Degradation
Biodegradable polymer degrades within the body as a result of 
natural biological processes, eliminating the need to remove a 
drug delivery system after the release of the active agent has 
been completed. Most biodegradable polymers are designed 
to degrade as a result of hydrolysis of the polymer chains into 
biologically acceptable and progressively smaller compounds. 
For some degradable polymers, most notably the Polyanhydrides 
and Polyorthoesters, the degradation occurs only at the surface of 
the polymer, resulting in a release rate that is proportional to the 
surface area of the drug delivery system.
Swelling
They are initially dry and when placed in the body will absorb water 
or other body fluids and swell. The swelling increases the aqueous 
solvent content within the formulation as well as the polymer mesh 
size, enabling the drug to diffuse through the swollen network into 
the external environment.[18]
Drug Release Mechanism of Sustained-release Drug 
Delivery Systems
Zero Order Kinetics
A zero-order release would be predicted by the following 
equation,
Qt – Qo= Kot
Where,
Qt = Amount of drug release dissolved in time’t’.
Qo = Initial amount of drug concentration in solution. 
Kot = Zero-order rate constant.
When the data were plotted as cumulative % drug release verses 
time, if the plot is linear, then data obeys zero-order kinetics with 
slope equal to Ko. This model represents an ideal release profile to 
achieve prolonged pharmacological action.
First Order Kinetics
A first-order release would be predicted by the following equation
                                                       t       
          Log Qt = log Qo – K1 ––––––––        
                                                   2.303
Where,
Qt = Amount of drug released in time’t’.
QO = Initial amount of drug concentration in solution. 
K1t = First order rate constant.
When data were plotted as cumulative log % drug remaining versus 
time yields a straight line indicating that the release follows first-order 
kinetics, the constant K can be obtained multiplying slope values.
Higuchi’s Model
Drug release from the matrix device by diffusion has been described 
by Higuchi’s Diffusion equation
 ft = Q = A  (D(2C-Cs)Cst) 
Where,
Q = Amount of drug released in time’t’.
D = Diffusion coefficient of the drug in the matrix. 
Cs = Solubility of the drug in the matrix.
A = Porosity of matrix. 
t = Tortuosity.
t = Time (h).
Peppas Korsmeyer Equation
In 1983 Korsmeyer et al. (Korsmeyer et al., 1983) developed a 
simple, semi-empiric model, when diffusion is the main drug 
release mechanism, relating exponentially the drug release to the 
elapsed time (t).
Mt/Ma =Kt
n
Where,
K = Constant. 
n = Release.
t = Time
Mt and Ma = Absolute cumulative amount of drug released at 
time ’t’.This is used when the release mechanism is not well known 
or when more than one type of release phenomenon could be 
involved.
Hixon-crowell Equation
Drug released from the matrix device by diffusion has been 
described by Hixon-Crowell diffusion equation;
Wo
1/3 – Wt
1/3Kt
Where,
W0 = Initial amount of drug.
Wt = Remaining amount of drug. t = Time.
K = Constant (Kappa).
Figure 4: Schematic illustrations of diffusion, degradation, and swelling release mechanisms
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This expression applies to pharmaceutical dosage form such as 
tablets where the dissolution occurs in planes that are parallel to 
drug surface if tablet dimensions diminish proportionally in such 
manner that the initial geometrical form keeps constant all the 
time.[19]
Novel Trends in Sustained Release Drug Delivery 
Systems
For orally administered dosage forms, sustained drug action is 
achieved by affecting the rate at which the drug is released from 
the dosage form and or by slowing the transit time of dosage form 
through the gastrointestinal tract.
Single Unit Dosage Forms
This refers to diffusion controlled system where the therapeutic 
agent is evenly distributed (Dispersed/dissolved) throughout 
the solid matrix. This system can be classif ied as follows: 
Complex reservoir system or coated tablets or multi-layered 
system.
Hydrophobic/Swellable tablets
Optimum alkaloid such as morphine salts homogenized with its salt 
and fatty acid or any ethylene vinyl acetate copolymer (hydrophobic 
filler) and then compressed into tablets.
Semisolid Matrix Systems
In this system drug is incorporated in an oily “semisolid” 
hydrophobic carrier, and finally mass is typically filled into a gelatin 
capsule to prepare dosage form.
Ion Exchange Resins
The system is composed of a core tablet surrounded by a 
semipermeable membrane coating having a 0.4 mm diameter hole 
produced by laser beam. The tablet, particle or drug solution that 
allows transport of water into tablet with eventual pumping of drug 
solution out of the tablet through the small deliveryaperture in 
tablet coating. E.g. Glucotrol XL (glipizide) tablets (Pfizer), Covera– 
HS ® (verapamil HCl) tabs. (Searle).[20,21]
Multiple Unit Dosage Forms
It represents a mixture of the dosage form, the source of which 
may either be homogenous or heterogeneous. The various 
forms which are available are multitablet system. Small spheroids 
compressed tablets 3–4 mm in diameter may be prepared to 
have varying drug release characteristics. They them may be 
placed in gelatin capsule shells to provide the desired pattern of 
drug release coated beads, granules and microsphere In these 
systems, the drug is distributed on to beads, pellets, granules, or 
other particulate systems. Using conventional pan coating or air 
suspension coating, a solution of the drug substance is placed on 
small inert nonpareil seeds or beads made of sugar and starch or on 
microcrystalline cellulose spheres. Pellets prepared by coating inert 
drug pellet with film forming polymers. The drug release depends 
upon coating composition of polymers and amount of coatings. 
Microencapsulation is a process by which solids, liquids, or even 
gases may be enclosed in microscopic particles by formation of thin 
coatings of wall material around the substance. It utilizes principle 
of bioadhesion for optimum delivery of the drug fromthe device. 
Mucoadhesive system is suitable to increase the contact time of 
drug with absorbing membrane and localization of delivery of 
drug at targeted sites.[22]
Protein Drug Eluting Cardiovascular Stents
Protein-eluting cardiovascular stents represent another potential 
application of protein sustained- release technology. The chemical 
drugs used on current drug eluting stents, although prevent after- 
stenting restenosis; inhibit healing of the blood vessel endothelium 
damaged by stent installation. The delayed endothelium recovery 
causes incident bleeding and thrombus forming. Several proteins 
have been found effective to suppress vascular smooth muscle 
.proliferation and to stimulate vessel endothelium recovery when 
directly introduced to the stenting site. However, loading these 
proteins onto stents resulted in ineffectiveness. In these work, stents 
precoated with a layer of hydrophobic polymer was impregnated 
in a protein solution to adsorb proteins on the polymer surface. 
However, adsorbing proteins on hydrophobic polymer surfaces 
is a known cause for protein denaturing In addition, only limited 
amount of proteins can be adsorbed on a stent surface (< 20 μg/
stent).[23]
Sustained release injectable formulations
Development of Sustained release injectable hasoccurred in 
the past few years. This was brought into existence to prolong 
the effect of drug at targeted site. This advancement also offers 
reducing dosing frequency, maximizing the efficacy– dose 
relationship, decreasing adverse side effects and enhancing 
Table 2: Examples of Various SR DDS Approaches.[25]
Sr. No. Type of device Product name Active ingredient Route Manufacturer
1. Diffusion  (reservoir) Estraderm Estradiol Transdermal Alza/Novartis
Norplant Levonorgestrel Sub-dermal implant Wyeth-ayerst laboratory
Ocusert Pilocarpine Ocular Alza
Progestasert Progesterone Intrauterine Alza
2. Diffusion (matrix) Nitro-Dur Nitroglycerine Transdermal Key Pharmaceutical
Nitrodisc Nitroglycerine Transdermal Searle
3. Mixed (matrix reservoir) Catapress-TTS Clonidine Transdermal Alza/BoehingerIngelheim
4. Hydro Dynamically MedoparCR Levodopa and 
Benserazide
Oral tablet Roche
5. Ion exchange Colestid Colestipol Oral tablet or Granules Upjohn
6. Coating Compazin Prochlorperazine Oral capsules Smith Kline Beecham
7. Nanocrystal technology Rapamune Sirolimus Oral tablet Elan/Wyefh-Ayerst 
Laboratory
8. Osmotic pumps Calan SR Verapamil Oral tablet Alza/G. D. Searle
Oral Sustained Release Tablets: An Overview With A Special Emphasis On Matrix Tablet
International Journal of Health and Biological Sciences, Jan-Mar, 2020; 3(1):06-1312
patient compliance. This system also leads to alleviation of pain 
during administration and reducing costing of parenteral drug 
treatment. Safety issues relating to an injectable sustained-release 
system cannot be overlooked. Premature termination of treatment 
in case of drug toxicity can be extremely difficult for most of the 
parenteral sustained-release systems once administered. The 
adverse response of local tissues to the drug and/or the system 
on prolonged exposure can be clinically alarming. In recent years, 
the research in parenteral sustained- release technologies has 
been fuelled mainly by the advent of novel carriers. The growth 
of injectable sustained-release products in the pharmaceutical 
marketplace is also evidenced by the increasing number of products 
that have been granted regulatory approval during the last 5 
years.[24] Table 2 gives examples of various SR DDS.
dIscussIon
The present article is focused on a sustained release matrix tablet. 
The goal of sustained-release could be easily and effectively 
ascertained via the approach of matrix tablets. As compared to 
conventional counterparts, matrix tablets offer better patient 
compliance, maintains constant plasma drug concentration level, 
reduces chances of toxicity, and once a day, drug therapy reduces 
the overall cost of treatment. Maintenance of drug concentration 
within a therapeutic range helps minimize the irrational use of 
drugs (esp. antibiotics) as well as helpful in the treatment of chronic 
diseases. Furthermore, it is a cost-effective approach.
conclusIon
It is concluded that oral sustained-release tablets provide the drug 
release in a modified form than their counterparts. It is effective to 
ascertain the therapeutic goals with maximum patient compliance. 
However, accurate adjustment of various physicochemical 
parameters is necessary. Matrix tablet is helpful in overcoming the 
problems associated with the conventional dosage form. Apart from 
various advantages associated with it cost-effective and once, daily 
dose is the key benefits associated with it. Due to its key benefits 
and better patient compliance, it can easily lead the market by 
replacing its counterparts.
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